Navigation Links
Preclinical Update - Debio-0512 Therapeutic Vaccine for the,Treatment of Chronic and Acute Inflammatory Conditions

Proof of Concept in Mice Transgenic for Human TNFa

LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, announces the presentation of preclinical results that validate the mechanism of action of Debio-0512 as an anti-TNFa therapeutic vaccine, that inhibits inflammatory processes in animal models of acute and chronic inflammation. Debio-0512 is a keyhole limpet hemocyanin (KLH)-human TNFa heterocomplex (hTNFa kinoid). The results of this study, published recently in the Proceedings of the National Academy of Sciences (PNAS), were presented on March 10 at the 4th International Conference on Tumor Microenvironment in Florence, Italy.

"These results confirm that therapeutic vaccination against human TNFa could represent in the future, an effective approach for the treatment of TNFa-dependent inflammatory pathologies including rheumatoid arthritis and Crohn's disease," said Professor Daniel Zagury of the University Pierre et Marie Curie (Paris) and co-author of the report. "Debiopharm's plan is for IND enabling clinical studies to be ready by the end of this year. We believe that active immunization may offer advantages over passive anti-TNFa monoclonal antibody therapy, by potentially limiting therapeutic failure related to the formation of anti-idiotypic antibodies. Moreover, the potential low frequency of boost immunizations would increase patient compliance."

TNFa is a well-established pro-inflammatory mediator. In hTNFa expressing transgenic mice (TTg mice), a mouse model of rheumatoid arthritis, animals receiving the Debio-0512 therapeutic vaccine developed high levels of anti-TNFa antibodies, neutralising both TNFa bioactivity and binding of TNFa to its receptor. This study shows that immunization with Debio-0512 effectively controls pathogenic effec ts triggered by TNFa in this mouse model of rheumatoid arthritis.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: www.debiopharm.com.

CONTACT: Debiopharm S.A. Contacts: Herve Porchet, VP, Medical Affairs,Tel.: +41-21-321-01-11, Fax: +41-21-321-01-69, . KimBill, VP, Business & Legal Affairs, . Additional MediaContacts: In London: Maitland, Brian Hudspith, Tel: +44-(0)20-7379-5151,. In New York: Noonan Russo, Wendy Lau, Tel:+1-212-845-4272, Fax: +1-212-845-4260, hporchet@debio.com kbill@debio.com bhudspith@maitland.co.uk wendy.lau1@eurorscg.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Xyntek Inc. has announced another milestone in their ... Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams ... ... engagements regionally. ...
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:9/1/2017)... will present the latest research from across its growing oncology ... Congress, September 8-12 in Madrid, Spain . ... on Bayer,s marketed portfolio and late-stage compounds as well as ... "We value the opportunity to meet with ... said Carsten Brunn , Head of Pharmaceuticals, Americas Region ...
Breaking Medicine Technology:
(Date:9/20/2017)... (PRWEB) , ... September 20, ... ... a software company specializing in medical device compliance and commercialization, has just ... risk management activities. , FDA is more adamant than ever about medical ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... innovation, the company recently unveiled a redesigned website. The new site – still ... of building owners, architects, contractors and other industry users that Garland serves. , ...
(Date:9/20/2017)... ... September 20, 2017 , ... The ... “Humans With Vaginas.” The goal is to ignite conversation via social media and ... products. The brand has declared September “Humans with Vaginas” month, releasing a video ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Health & ... and 30-Hour and HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, ... In addition to offering these discounted prices to all businesses and government agencies – ...
(Date:9/20/2017)... ... 20, 2017 , ... “Finn Mouseson”: follows the exciting story of a mouse ... mouse sets out on a journey that will show that friends are to be ... newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in ...
Breaking Medicine News(10 mins):